Rain Enhancement Stock Price, News & Analysis

Rain Therapeutics Inc. (NasdaqGS: RAIN) is scheduled to present at the Cantor Fitzgerald Virtual Global Healthcare Conference from September 27-30, 2021. CEO Avanish Vellanki will lead the presentation on September 30, 2021, at 10:00 a.m. ET, which can be accessed via a webcast link or through Rain's website. The event aims to showcase Rain’s advancements in precision oncology therapeutics, including their lead product candidate, milademetan, a small molecule oral inhibitor targeting MDM2. A replay will be available on their website for 30 days after the event.

Rain Therapeutics Inc. (NasdaqGS: RAIN) announced that CEO Avanish Vellanki will present at the H.C. Wainwright 23rd Annual Global Investment Conference, occurring virtually from September 13-15, 2021. Vellanki's presentation is scheduled for September 13 at 7:00 a.m. ET. Interested parties can access the presentation via a webcast link or through the Rain website. A replay will be available for 30 days post-event. Rain focuses on precision oncology, developing therapies like milademetan, a small molecule MDM2 inhibitor, targeting various cancers.

Rain Therapeutics announced promising non-clinical data on its oral MDM2 inhibitor, milademetan (RAIN-32), at the IASLC 2021 World Conference on Lung Cancer. The findings indicate that milademetan treatment effectively targets malignant pleural mesothelioma (MPM), showcasing differential sensitivity based on genetic profiles. Increased p53 protein levels were noted in sensitive cell lines, and significant growth reduction was observed in MPM xenografts. Rain aims to address the unmet medical needs of MPM patients, particularly post anti-PD1 therapy.

Rain Therapeutics Inc. (NASDAQ: RAIN), a late-stage precision oncology firm, is presenting at the IASLC 2021 World Conference on Lung Cancer from September 8-14, 2021. The poster, titled The MDM2/p53 axis is a therapeutic vulnerability in malignant pleural mesothelioma, will be presented by Dr. Lynn Heasley on September 8. Additionally, Avanish Vellanki will participate in a Targeted Oncology Panel at the Citi 16th Annual Biopharma Conference on September 10. Recordings will be available on the Rain website post-event.

Rain Therapeutics (RAIN) has initiated the Phase 3 MANTRA clinical trial for milademetan in patients with dedifferentiated liposarcoma, marking a significant milestone achieved under a year after acquiring the program. The company reported a quarter-end cash position of $164.6 million, ensuring funding through late 2024. Despite a net loss of $8.2 million for Q2 2021, up from $2.6 million in 2020, management remains optimistic about future trials and collaborations aimed at enhancing patient outcomes and anticipate interim results from their upcoming studies.

Rain Therapeutics Inc. (NasdaqGS: RAIN) is set to release its second-quarter financial results on August 10, 2021. The management will host a conference call at 1:30 PM PT to discuss the financial outcomes and business developments. Rain Therapeutics focuses on precision oncology therapies, utilizing a tumor-agnostic strategy to select patients based on genetic profiles, with its leading candidate being milademetan (RAIN-32), an MDM2 inhibitor. Investors and stakeholders can participate in the call via dial-in or a webcast link provided in the announcement.

Rain Therapeutics has announced the commencement of a Phase 3 trial (MANTRA) evaluating milademetan (RAIN-32) in patients with de-differentiated liposarcoma (DD LPS). This pivotal study, which aims to showcase the efficacy of milademetan against the standard treatment, trabectedin, is set to involve approximately 160 patients. Notably, previous studies show that patients have experienced long-term therapy for over 4 years with milademetan, indicating a favorable safety profile. The trial focuses on progression-free survival, aiming to fulfill a significant unmet medical need.

Rain Therapeutics Inc. has announced a partnership with Tempus to enhance its Phase 2 clinical trial for RAIN-32, targeting MDM2-amplified tumors. The trial is set to commence in the second half of 2021, focusing on utilizing Tempus' genomic analysis platform for patient matching and tumor profiling. RAIN-32, an oral MDM2 inhibitor, demonstrated significant anti-tumor activity in previous trials. The company plans to initiate a pivotal Phase 3 trial for liposarcoma and a Phase 2 tumor-agnostic basket trial later this year. RAIN-32 has already received FDA Orphan Drug Designation.

Rain Therapeutics has partnered with Caris Life Sciences to enhance patient referrals for its upcoming Phase 2 clinical trial of RAIN-32, an oral MDM2 inhibitor targeting cancers with MDM2 amplification. Set to begin in H2 2021, this novel trial will leverage Caris' molecular profiling technology to identify eligible patients across various solid tumors. Additionally, RAIN-32 has shown promising antitumor activity in prior studies, leading to plans for a pivotal Phase 3 trial in liposarcoma. The FDA has granted RAIN-32 Orphan Drug Designation, underscoring its potential.